Robert Andrew Holt: Difference between revisions
m Kvng moved page Draft:Robert Andrew Holt to Robert Andrew Holt: Publishing accepted Articles for creation submission (AFCH 0.9.1) |
m Moving from Category:Cancer researchers to Category:Canadian cancer researchers using Cat-a-lot |
||
| (12 intermediate revisions by 8 users not shown) | |||
| Line 1: | Line 1: | ||
{{Multiple issues| |
|||
{{AFC submission|||u=Kvng|ns=118|demo=|ts=20200422211148}} <!-- Do not remove this line! --> |
|||
{{Like resume|date=October 2020}} |
|||
{{POV|date=October 2020}} |
|||
}} |
|||
| ⚫ | '''Robert Holt''', (born July 22, 1968 in New Westminster, BC, Canada) is a genomic scientist and immunogeneticist. He is currently a Distinguished Scientific at the [[BC Cancer Research Centre]], where he is also Co-Director of the BC Cancer Immunotherapy program (in [[Vancouver]], [[Canada]]). He is also appointed as Professor of Medical Genetics at the [[University of British Columbia]] and Professor of Molecular Biology & Biochemistry at [[Simon Fraser University]]. Through international consortia, he has had made several significant contributions to science (e.g. [[The Cancer Genome Atlas]], The Human [[Microbiome]] Project, Cancer Research UK Grand Challenges). After initial [[sequencing]] of the [[Drosophila]]<ref name="ref1"/> and human genomes <ref name="ref2"/> was co-PI on the NIH program to sequence the [[rat]] [[genome]],<ref name="ref3"/> and was also a PI on the international effort to sequence the [[malaria]] mosquito genome,<ref name="ref4"/> which involved >30 principal scientists from 11 different countries. With his publications exceeding over 200 and his citations being recorded approximately 70,000 times, Holt earned a position in the top 1% of [[Web of Science]] cited researchers by [[Clarivate]] Analytics in 2018 and 2019. |
||
=Robert Andrew Holt= |
|||
| ⚫ | |||
=Education= |
==Education== |
||
After earning an undergraduate degree (BSc) in General Science from the University of British Columbia in 1992, he studied [[neuroscience]] and [[pharmacology]] under the supervision of Drs. Ian L. Martin and Alan N. Bateson at the [[University of Alberta]] and graduated with a PhD in Pharmacology in 1998. His thesis focused on the molecular characterization of [[GABA-A receptors]]. He undertook postdoctoral research at the [[State University of New York]] in Albany with Dr. Caro-Beth Stewart, where he used rapid [[DNA sequencing]] techniques to study [[molecular evolution]] in [[primates]]. |
After earning an undergraduate degree (BSc) in General Science from the University of British Columbia in 1992, he studied [[neuroscience]] and [[pharmacology]] under the supervision of Drs. Ian L. Martin and Alan N. Bateson at the [[University of Alberta]] and graduated with a PhD in Pharmacology in 1998. His thesis focused on the molecular characterization of [[GABA-A receptors]]. He undertook postdoctoral research at the [[State University of New York]] in Albany with Dr. Caro-Beth Stewart, where he used rapid [[DNA sequencing]] techniques to study [[molecular evolution]] in [[primates]]. |
||
=Career= |
==Career== |
||
Throughout his undergraduate and graduate studies, for several months each year, he worked in the [[silviculture]] industry in northern [[British Columbia]]. After his brief postdoctoral research program he joined Dr. Craig Venter's team at [[Celera Genomics]], as the production manager for DNA sequencing operations. He was a leading figure actualizing industrial-scale molecular biology and established, at the time, the world's largest DNA sequencing center. Upon his return to Canada, he joined the Michael Smith Genome Sciences Centre (GSC), a world-leading genome center with >300 personnel, at the [[BC Cancer Research Centre]]. He served as Head of Sequencing and co-Director (with Dr. Marco Marra) of the Genome Canada Innovation Network GSC node from 2005 to 2016. Together with Medical Director A. Karsan, he established the first College of American Pathologists-accredited clinical next generation sequencing (NGS) platform in Canada. |
Throughout his undergraduate and graduate studies, for several months each year, he worked in the [[silviculture]] industry in northern [[British Columbia]]. After his brief postdoctoral research program he joined Dr. Craig Venter's team at [[Celera Genomics]], as the production manager for DNA sequencing operations. He was a leading figure actualizing industrial-scale molecular biology and established, at the time, the world's largest DNA sequencing center. Upon his return to Canada, he joined the Michael Smith Genome Sciences Centre (GSC), a world-leading genome center with >300 personnel, at the [[BC Cancer Research Centre]]. He served as Head of Sequencing and co-Director (with Dr. Marco Marra) of the Genome Canada Innovation Network GSC node from 2005 to 2016. Together with Medical Director A. Karsan, he established the first College of American Pathologists-accredited clinical next generation sequencing (NGS) platform in Canada. |
||
He joined the faculty of the University of British Columbia in 2003 where he is now a Professor in the Department of [[Medical Genetics]], a Faculty Member of the Genome Science and Technology program, the Interdisciplinary Oncology Graduate Program, the Genetics Graduate Program and the Health Brain Research Centre. He is also a Professor in the [[Molecular Biology]] and [[Biochemistry]] Department at Simon Fraser University. |
He joined the faculty of the University of British Columbia in 2003 where he is now a Professor in the Department of [[Medical Genetics]], a Faculty Member of the Genome Science and Technology program, the Interdisciplinary Oncology Graduate Program, the Genetics Graduate Program and the Health Brain Research Centre. He is also a Professor in the [[Molecular Biology]] and [[Biochemistry]] Department at Simon Fraser University. |
||
| Line 14: | Line 16: | ||
Moreover, together with Dr. Brad Nelson, he is currently Scientific Co-Director of the [[BC Cancer]] [[Immunotherapy]] program. With Dr. John Bell (Univ. of Ottawa) and others he launched BioCanRx, a Networks of Centres of Excellence program focused on cancer biotherapeutics. He serves as overall PI for a team of basic and clinical scientists in BC and [[Ontario]] that has established domestic [[CAR-T]] manufacturing capacity and launched the first investigator-initiated, self-sponsored CAR-T [[clinical trial]] in Canada "CLIC-01" laying the groundwork for new CAR-T innovations in Canada. |
Moreover, together with Dr. Brad Nelson, he is currently Scientific Co-Director of the [[BC Cancer]] [[Immunotherapy]] program. With Dr. John Bell (Univ. of Ottawa) and others he launched BioCanRx, a Networks of Centres of Excellence program focused on cancer biotherapeutics. He serves as overall PI for a team of basic and clinical scientists in BC and [[Ontario]] that has established domestic [[CAR-T]] manufacturing capacity and launched the first investigator-initiated, self-sponsored CAR-T [[clinical trial]] in Canada "CLIC-01" laying the groundwork for new CAR-T innovations in Canada. |
||
=Research= |
==Research== |
||
His lab described the link between an emerging [[pathogen]], [[Fusobacterium nucleatum]] (Fn), and [[colorectal cancer]] |
His lab described the link between an emerging [[pathogen]], [[Fusobacterium nucleatum]] (Fn), and [[colorectal cancer]].<ref name="ref5"/> This finding (named by [[TIME magazine]] as one of the top 10 medical breakthroughs for 2011) has been extensively replicated and its significance has gained a global renown. He leads one of six work-packages in a newly awarded Cancer Research UK Grand Challenges grant where their international team will interrogate Fn biology comprehensively in global cohorts and model systems. |
||
His group pioneered decoding [[immune repertoire]] by deep sequencing<ref name="ref6"/> |
His group pioneered decoding [[immune repertoire]] by deep sequencing,<ref name="ref6"/> opening a fast-developing field <ref name="ref7"/><ref name="ref8"/> encompassing numerous [[biotechnology]] companies, holding international meetings and establishing a scientific society mainly focused on this methodology. Their work also profiled [[T-lymphocyte]] [[antigens]], as well.<ref name="ref9"/> They led the way to develop an NGS assembly algorithm <ref name="ref10"/> and succeeded in extracting [[Human Leukocyte Antigen]] (HLA) types from NGS data sets.<ref name="ref11"/> These methods have been utilized by themselves and by the community in recent high impact studies.<ref name="ref12"/><ref name="ref13"/> They were also the first to show that the anti-cancer immune response is linked to mutational antigen (neoantigen) load.<ref name="ref14"/> Neoantigens are now being thoroughly scrutinized as targets for cancer immunotherapy and are implicated in the achievements of the new blockbuster [[checkpoint blockade]] therapies. |
||
=References= |
==References== |
||
<references> |
<references> |
||
<ref name="ref1"> |
<ref name="ref1"> |
||
| Line 30: | Line 32: | ||
Keener, AB, A sense of immunity: scientists are detailing the immune system as never before. Nat Med, 2015. 21:3-8.</ref><ref name="ref8"> |
Keener, AB, A sense of immunity: scientists are detailing the immune system as never before. Nat Med, 2015. 21:3-8.</ref><ref name="ref8"> |
||
Holt, RA, Interpreting the T cell repertoire. Nat Biotechnol. 2017. 35:829</ref><ref name="ref9"> |
Holt, RA, Interpreting the T cell repertoire. Nat Biotechnol. 2017. 35:829</ref><ref name="ref9"> |
||
Sharma G et al., Rapid selection and |
Sharma G et al., Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries. Nat Comm, 2019. 10:4553</ref><ref name="ref10"> |
||
Warren RL et al., Assembling millions of short DNA sequences using SSAKE. Bioinformatics, 2007. 23:500</ref><ref name="ref11"> |
Warren RL et al., Assembling millions of short DNA sequences using SSAKE. Bioinformatics, 2007. 23:500</ref><ref name="ref11"> |
||
Warren RL et al., Derivation of HLA types from shotgun sequence datasets. Genome Med, 2012. 4(12): p. 95.</ref><ref name="ref12"> |
Warren RL et al., Derivation of HLA types from shotgun sequence datasets. Genome Med, 2012. 4(12): p. 95.</ref><ref name="ref12"> |
||
| Line 38: | Line 40: | ||
</ref> |
</ref> |
||
</references> |
</references> |
||
{{DEFAULTSORT:Holt, Robert}} |
|||
[[Category:1968 births]] |
|||
[[Category:Living people]] |
|||
[[Category:21st-century Canadian scientists]] |
|||
[[Category:Canadian cancer researchers]] |
|||
Latest revision as of 10:18, 7 April 2024
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Robert Holt, (born July 22, 1968 in New Westminster, BC, Canada) is a genomic scientist and immunogeneticist. He is currently a Distinguished Scientific at the BC Cancer Research Centre, where he is also Co-Director of the BC Cancer Immunotherapy program (in Vancouver, Canada). He is also appointed as Professor of Medical Genetics at the University of British Columbia and Professor of Molecular Biology & Biochemistry at Simon Fraser University. Through international consortia, he has had made several significant contributions to science (e.g. The Cancer Genome Atlas, The Human Microbiome Project, Cancer Research UK Grand Challenges). After initial sequencing of the Drosophila[1] and human genomes [2] was co-PI on the NIH program to sequence the rat genome,[3] and was also a PI on the international effort to sequence the malaria mosquito genome,[4] which involved >30 principal scientists from 11 different countries. With his publications exceeding over 200 and his citations being recorded approximately 70,000 times, Holt earned a position in the top 1% of Web of Science cited researchers by Clarivate Analytics in 2018 and 2019.
Education
[edit]After earning an undergraduate degree (BSc) in General Science from the University of British Columbia in 1992, he studied neuroscience and pharmacology under the supervision of Drs. Ian L. Martin and Alan N. Bateson at the University of Alberta and graduated with a PhD in Pharmacology in 1998. His thesis focused on the molecular characterization of GABA-A receptors. He undertook postdoctoral research at the State University of New York in Albany with Dr. Caro-Beth Stewart, where he used rapid DNA sequencing techniques to study molecular evolution in primates.
Career
[edit]Throughout his undergraduate and graduate studies, for several months each year, he worked in the silviculture industry in northern British Columbia. After his brief postdoctoral research program he joined Dr. Craig Venter's team at Celera Genomics, as the production manager for DNA sequencing operations. He was a leading figure actualizing industrial-scale molecular biology and established, at the time, the world's largest DNA sequencing center. Upon his return to Canada, he joined the Michael Smith Genome Sciences Centre (GSC), a world-leading genome center with >300 personnel, at the BC Cancer Research Centre. He served as Head of Sequencing and co-Director (with Dr. Marco Marra) of the Genome Canada Innovation Network GSC node from 2005 to 2016. Together with Medical Director A. Karsan, he established the first College of American Pathologists-accredited clinical next generation sequencing (NGS) platform in Canada.
He joined the faculty of the University of British Columbia in 2003 where he is now a Professor in the Department of Medical Genetics, a Faculty Member of the Genome Science and Technology program, the Interdisciplinary Oncology Graduate Program, the Genetics Graduate Program and the Health Brain Research Centre. He is also a Professor in the Molecular Biology and Biochemistry Department at Simon Fraser University.
Moreover, together with Dr. Brad Nelson, he is currently Scientific Co-Director of the BC Cancer Immunotherapy program. With Dr. John Bell (Univ. of Ottawa) and others he launched BioCanRx, a Networks of Centres of Excellence program focused on cancer biotherapeutics. He serves as overall PI for a team of basic and clinical scientists in BC and Ontario that has established domestic CAR-T manufacturing capacity and launched the first investigator-initiated, self-sponsored CAR-T clinical trial in Canada "CLIC-01" laying the groundwork for new CAR-T innovations in Canada.
Research
[edit]His lab described the link between an emerging pathogen, Fusobacterium nucleatum (Fn), and colorectal cancer.[5] This finding (named by TIME magazine as one of the top 10 medical breakthroughs for 2011) has been extensively replicated and its significance has gained a global renown. He leads one of six work-packages in a newly awarded Cancer Research UK Grand Challenges grant where their international team will interrogate Fn biology comprehensively in global cohorts and model systems.
His group pioneered decoding immune repertoire by deep sequencing,[6] opening a fast-developing field [7][8] encompassing numerous biotechnology companies, holding international meetings and establishing a scientific society mainly focused on this methodology. Their work also profiled T-lymphocyte antigens, as well.[9] They led the way to develop an NGS assembly algorithm [10] and succeeded in extracting Human Leukocyte Antigen (HLA) types from NGS data sets.[11] These methods have been utilized by themselves and by the community in recent high impact studies.[12][13] They were also the first to show that the anti-cancer immune response is linked to mutational antigen (neoantigen) load.[14] Neoantigens are now being thoroughly scrutinized as targets for cancer immunotherapy and are implicated in the achievements of the new blockbuster checkpoint blockade therapies.
References
[edit]- ^ Adams, MD, Celniker SE, Holt, RA, et al., The genome sequence of Drosophila melanogaster. Science, 2000. 287: 2185 Breakthrough of the Year (Science 290:2255).
- ^ Venter, JC, Adams, MD, Meyers, EW, Li, PW, Mural, RJ, Sutton, GG, Smith, HO, Yandell, M, Evans, CA, Holt, RA, et al., The sequence of the human genome. Science, 2001. 291:1304
- ^ The Rat Genome Sequencing Project Consortium.. Nature, 2004. 428:493
- ^ Holt, RA, et al., The genome sequence of the malaria mosquito Anopheles gambiae. Science, 2002. 298:129
- ^ Castellarin M et al., F.nucleatum infection is prevalent in human colorectal carcinoma. Genome Res, 2012. 22:299
- ^ Freeman JD et al.,. Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res, 2009. 19:1817
- ^ Keener, AB, A sense of immunity: scientists are detailing the immune system as never before. Nat Med, 2015. 21:3-8.
- ^ Holt, RA, Interpreting the T cell repertoire. Nat Biotechnol. 2017. 35:829
- ^ Sharma G et al., Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries. Nat Comm, 2019. 10:4553
- ^ Warren RL et al., Assembling millions of short DNA sequences using SSAKE. Bioinformatics, 2007. 23:500
- ^ Warren RL et al., Derivation of HLA types from shotgun sequence datasets. Genome Med, 2012. 4(12): p. 95.
- ^ Zhang AW et al., Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell. 2018. 173:1755
- ^ Thorsson V, et al., The Immune Landscape of Cancer. Immunity. 2018 48(4): p. 812-830
- ^ Brown SD et al., Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res, 2014. 24:743-50.